Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.4536
-0.0063 (-1.37%)
Sep 4, 2025, 2:59 PM - Market open
Plus Therapeutics Stock Forecast
PSTV's stock price has decreased by -69.89% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts that cover Plus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.88, which forecasts a 1,637.21% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $20.5.
Price Target: $7.88 (+1,637.21%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Plus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +1,002.29% | Sep 3, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +561.38% | Aug 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5.5 → $3 | Strong Buy | Maintains | $5.5 → $3 | +561.38% | Jun 27, 2025 |
| D. Boral Capital | D. Boral Capital | Hold Maintains $9 | Hold | Maintains | $9 | +1,884.13% | Jun 25, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $20 → $21 | Strong Buy | Maintains | $20 → $21 | +4,419.40% | Jun 5, 2025 |
Financial Forecast
Revenue This Year
6.00M
from 5.82M
Increased by 2.95%
Revenue Next Year
6.47M
from 6.00M
Increased by 7.89%
EPS This Year
-0.67
from -2.34
EPS Next Year
-0.36
from -0.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.9M | 12.7M | |||
| Avg | 6.0M | 6.5M | |||
| Low | 3.9M | 3.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 69.4% | 112.1% | |||
| Avg | 3.0% | 7.9% | |||
| Low | -32.7% | -34.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.58 | -0.05 | |||
| Avg | -0.67 | -0.36 | |||
| Low | -0.80 | -0.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.